Treatment with candesartan decreased RBP-4 and resistin levels and increased visfatin but no significant changes were observed with olmesartan treatment in overweight hypertensive patients with type 2 diabetes [22]. The gene discussed is NAMPT; the disease is type 2 diabetes mellitus.